Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA/
      2. European Commission Approves SYLVANT® (siltuximab) as MCD Treatment

      European Commission Approves SYLVANT® (siltuximab) as MCD Treatment

      May 14, 2015
      1 min read

      European Commission Approves SYLVANT® (siltuximab) as a Treatment for Patients with Multicentric Castleman’s Disease (MCD)